3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Precision Optics Corporation entered a one-year lease with Equity Assets, Inc. for its existing 12,292-square-foot Gardner, Massachusetts location, with a term starting July 1, 2026. Monthly base rent rises from $13,316.33 to $13,715.82 on January 1, 2027, and the lease includes two one-year extension options.
Lease signed October 28, 2026; term commences July 1, 2026 for one year
Monthly rent is $13,316.33 through December 31, 2026, then $13,715.82 in 2027, with 3.0% annual increases after that
Company pays personal property taxes; landlord pays real estate taxes and assessments
Two one-year extension options require at least six months' prior written notice
A Pro-Dex subsidiary, Advanced Precision Machining, renewed three existing Costa Mesa, California leases through September 30, 2030, with base rent increases starting February 1, 2027. It also signed a new lease for an industrial unit of about 5,800 square feet starting November 1, 2026. The filing describes routine facility agreements and does not report financial results, so it gives shareholders no direct earnings information.
Lease Renewals signed October 26, 2026, covering about 2,500 square feet at 1645, 1647 and 1649 Monrovia Avenue, extending the leases to September 30, 2030
Base rent rises 4.0% to 6.6% starting February 1, 2027; for spaces 1647 and 1649, rent is $5,651 per month, and for space 1645, $5,513 per month, through October 31, 2028
New Lease signed October 29, 2026 with Salter Family Trust for about 5,800 square feet at 921-923 Newhall Street, with base rent of $11,600 per month from November 1, 2026
Hashdex Nasdaq CME Crypto Index ETF (NCIQ) disclosed that on October 27, 2026, Jane Street Capital, LLC, one of its Authorized Participants, entered into an agreement with the Trust and its sponsor, Hashdex Asset Management Ltd. The agreement sets out the procedures for creating and redeeming Baskets of Common Shares. The filing is administrative and includes no financial results, fees, or dollar amounts.
Agreement dated October 27, 2026, between Jane Street Capital, LLC, the Trust and Hashdex Asset Management Ltd.
Agreement governs how Jane Street creates and redeems Baskets of Common Shares.
Full agreement filed as Exhibit 10.1 to the Form 8-K, signed October 30, 2026.
Green Plains entered into a Tax Credit Purchase Agreement on October 29, 2026, to transfer Section 45Z clean fuel production tax credits from its 2026 ethanol production to two unaffiliated buyers. The deal covers a minimum of $250 million and up to $325 million in credits, and the company expects $140 million of cash in the fourth quarter for credits generated through June 30, 2026.
Minimum of $250 million and maximum of $325 million in 2026 Section 45Z credits, subject to generation and conditions
Company expects $140 million cash in Q4 2026 for credits generated through June 30, 2026
Credits from Q3 and Q4 2026 expected to be monetized in the first half of 2027
If a tax law change limits transferred credits, Green Plains must return the related purchase price with interest
Moleculin Biotech announced that dosing is complete in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia. The company says it remains on track to report comprehensive Part A data in the first quarter of 2027, with the full 90-patient population used to select the Annamycin dose for Part B.
Dosing completed in Part A of the MIRACLE trial, which the company describes as a randomized, double-blind study with a 90-patient Part A population.
Comprehensive Part A data readout remains expected in the first quarter of 2027.
Final Part A population is expected to be about 50/50 between 7+3 chemotherapy and venetoclax-based regimen patients, versus about 70/30 among the first 45 subjects.
The filing states the company will require significant additional financing, for which it has no commitments.
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX on October 26, 2026, under which ZEO would receive an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, with Pluri receiving equity in ZEO at closing. On October 27, 2026, Pluri agreed to sell 909,092 common shares and warrants to two investors for $1.0 million in total, with closing expected on or before October 30, 2026. The stock sale adds shares outstanding, and the ZEO transaction depends on closing conditions, including agreement on an operating plan.
October 26, 2026: ZEO partnership grants ZEO an exclusive US license to manufacture and commercialize Pluri's regenerative medicine products, excluding certain aesthetics, skin care, cosmetic, or veterinary uses, which ZEO may only commerci
At closing, Pluri is to receive 41% of ZEO's issued and outstanding shares plus 50 Series D Preferred shares carrying 51% of ZEO's votes
October 27, 2026: two Securities Purchase Agreements for 909,092 common shares at $1.10 per share, with warrants for an equal number of shares at $1.30 per share; closing expected on or before October 30, 2026
Dermata Therapeutics said it enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment, in people with acne. The company expects to launch this second commercial product in the first half of 2027, and the filing ties the plan to a broader shift toward commercializing skincare products. The filing gives no financial figures, so the update is a development milestone rather than a change to reported results.
First participant enrolled in a clinical trial of Tome Clearing Treatment in people with acne, announced October 29
Tome Clearing Treatment is described as the company's once-weekly acne treatment and its second commercial product
Company expects to launch the product in the first half of 2027
Iovance updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial in previously treated non-squamous metastatic non-small-cell lung cancer, reporting a 24.6% objective response rate in 69 patients, consistent with the 25.6% previously reported. The company also introduced a retrospectively identified biomarker subgroup with a 59.1% response rate, a precision strategy that could change how the lung cancer program is developed and how the company plans its next trial.
Broader population: 24.6% objective response rate (17 of 69 patients), consistent with the 25.6% rate in 39 patients previously reported.
Retrospective biomarker subgroup (KRAS wild-type, HER2 wild-type, current or former smoker): 59.1% response rate (13 of 22 patients), including both complete responses.
POSITILITY study to begin enrollment in November 2026; supplemental Biologics License Application for non-squamous mNSCLC planned for 2027, subject to FDA discussions.
Eva Live Inc. announced on October 27, 2026 the launch of EvaSportsPredict, an AI-powered sports prediction platform covering baseball, football, hockey and basketball. The filing gives no financial figures for the product, so its effect on revenue or earnings cannot be measured from this document, though the company says it uses a subscription model and plans more Eva-powered products over the next several weeks.
Standard membership costs $19.99 per month after a 14-day free trial.
Supports professional and college baseball, football, hockey and basketball, with a separate model for each sport.
Company plans to introduce additional Eva-powered products over the next several weeks.
The 8-K was signed October 29, 2026 by David Boulette, President and CEO, and attaches the press release as Exhibit 99.1.
On October 28, 2026, Workhorse Group entered a Manufacturing Spec Unit Purchase Agreement under which UK-based RHAELM will pay $10 million over three installments to build a full-scale TerraPod manufacturing spec unit at the company's Union City, Indiana facility. A non-binding letter of intent targets a definitive supply agreement by December 31, 2026, and contemplates a contingent initial order for 150 TerraPod systems, but the filing states there is no assurance either will happen.
RHAELM will pay $10 million over three installments for a TerraPod manufacturing spec unit at Union City, Indiana.
Non-binding letter of intent targets signing a definitive supply agreement by December 31, 2026.
Contemplated contingent initial order for 150 TerraPod systems depends on the supply agreement, RHAELM's acceptance of the platform, definitive documentation and internal approvals.
Press release says Workhorse believes TerraPod production can begin in late 2027 or early 2028.
Mineralys Therapeutics and Tanabe Pharma terminated the License Agreement for lorundrostat on October 27, 2026, and Tanabe assigned the related patents and know-how to Mineralys. Mineralys remains obligated to pay Tanabe the milestone payments under a separate Payment Obligation Agreement, and Tanabe keeps a first-negotiation right for Japan. The filing says the company incurred no material early termination penalties, and the $100.0 million change-of-control payment is no longer tied to the license terms that existed before.
License Agreement terminated and Transferred Intellectual Property assigned to Mineralys on October 27, 2026
Mineralys still owes Tanabe commercial milestone payments of up to $255.0 million plus up to $10.0 million for a potential second indication
Tanabe's right of first negotiation survives for Japan while milestones remain unpaid
No material early termination penalties incurred; full agreements to be filed with the 2026 Form 10-K
Celularity Inc. announced on October 29, 2026, an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to make U.S.-based peptide active pharmaceutical ingredients under Vesalius's Peptual brand at Celularity's New Jersey facility. The filing does not disclose any financial terms, revenue expectations or contract value, so its effect on Celularity's financial results cannot be assessed from the filing.
Announced October 29, 2026; press release filed as Exhibit 99.1 to Form 8-K
Celularity performs downstream purification, processing, analytical testing and manufacturing at its Florham Park, New Jersey facility
Supply to U.S. compounding pharmacies is conditional on future FDA action following Pharmacy Compounding Advisory Committee recommendations
The collaboration will not involve GLP-1 receptor agonists or other weight-loss peptides
374Water Inc. furnished an updated October 2026 investor presentation and a related press release, both tied to the EPA's PFAS TECH Strategy launched October 26, 2026, which names supercritical water oxidation among technologies to advance. The filing contains no new financial results, guidance, or contract financial terms beyond previously referenced project figures, so the direct financial impact on shareholders is not quantified.
EPA Administrator Lee Zeldin launched the PFAS TECH Strategy on October 26, 2026, naming supercritical water oxidation among technologies to advance.
The presentation cites a U.S. Army Corps of Engineers report documenting 99.9993% total PFAS destruction in AFFF.
The filing lists a City of Olathe, KS order of about $4.8 million and a Mobile WDS contract with St. Cloud, MN of $600,000 completed in September 2026.
Orange County Sanitation District, CA AirSCWO deployment is planned for November 2026.
Canton Strategic Holdings announced an agreement with TSV LLC to make its common stock available for trading on TSV, a venue for tokenized NMS stocks on the Canton Network. Trading is expected to begin as early as Monday, November 2, and the shares would be tokenized by Fairmint as issuer-sponsored stock. The filing contains no financial results, and the company states the tokenized shares would carry the same rights as its Nasdaq-listed stock.
Trading on TSV is expected to begin as early as Monday, November 2, 2026.
Fairmint, an SEC-registered onchain transfer agent, will tokenize the shares as issuer-sponsored stock.
The company says tokenized holders would have the same rights and privileges as holders of its Nasdaq-listed stock.
The announcement follows the SEC's September 17 Innovation Exemption; the filing reports no financial figures.
Evolution Metals & Technologies (EMAT) announced it has secured about 754 metric tons of neodymium metal sourced outside China, which it says covers about 50% of the feedstock needed for its full-year 2027 revenue guidance of $400 million to $460 million. The filing is a furnished press release with no new financial results, so it gives no evidence yet that the feedstock supply is converting into revenue.
About 754 metric tons of neodymium metal secured, including about 42 metric tons already delivered to Pohang and a 600-metric-ton contract with Senri Trading.
About 520 kilograms of dysprosium metal held in Pohang, with 1.5 metric tons per month committed starting February 2027.
Company targets profitability in 2027 and plans a ribbon-cutting ceremony at Pohang on December 17, 2026.
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical on October 23, 2026, for the late-stage calpain inhibitor KIO-401, covering territories outside Asia. The deal calls for a $3.5 million upfront payment, a low-teen-million-dollar payment on technology transfer, and up to $168.5 million in milestones, and the company says it is evaluating financing to fund development. For shareholders, the filing adds near-term cash obligations and funding uncertainty, and it reports no revenue or earnings figures.
Upfront payment of $3.5 million to Senju, with a further low-teen-million-dollar payment upon technology transfer, a portion of which may be credited against future milestones.
Up to $168.5 million in additional regulatory and commercial milestone payments, plus single-digit royalties on net sales in the licensed territory.
Kiora discontinued research and development of KIO-104 and is evaluating financing alternatives to fund KIO-401 development.
Target initiation of the multinational Phase 3 CRAO trial is 2027, subject to funding and regulatory alignment.
Evolution Metals & Technologies (EMAT) said it submitted a capability statement to the U.S. Army's Sources Sought notice for rare earth magnets used in small drone motors. The notice is a market research request that does not commit the Army to any purchase, so the filing reports a submission rather than a contract award.
Submitted a capability statement on October 28, 2026, in response to the Army Contracting Command Sources Sought notice
The company says it commercially produces N42SH, one of the two grades the Army specified, at its Pohang, Korea facility
Plans to expand annual magnet capacity in Pohang from approximately 1,000 metric tons to approximately 10,000 metric tons, pending installation of ULVAC equipment
The Army notice states it is for planning purposes only and does not commit the Government to contract for any supply
Markel's insurance subsidiaries entered an Adverse Development Cover Agreement with Cavello Bay Reinsurance, a wholly owned subsidiary of Enstar Group Limited, covering $4.8 billion of net reserves on a run-off global reinsurance portfolio and certain exited lines. Markel will pay a $2.4 billion reinsurance premium, settled through a transfer of assets at closing, and the deal is expected to close by the end of the fourth quarter of 2026 subject to regulatory approval. Markel's press release says the net impact on fourth quarter underwriting results is expected to be immaterial.
Subject reserves of $4.8 billion; Markel retains the first $2.6 billion of covered losses, and the reinsurer covers the next $2.3 billion.
Adverse development coverage of $1.2 billion above the $4.8 billion of reserves.
Reinsurance premium of $2.4 billion, with $500 million of transferred assets sent to the reinsurer outright and the balance placed in a trust account.
Closing expected by the end of the fourth quarter of 2026, subject to regulatory approval; the agreement covers losses paid on or after April 1, 2026.
MetaVia Inc. announced that an abstract on Phase 1 clinical trial data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver, Colorado. The filing is an update on a clinical program and contains no financial results, guidance, or transaction terms.
Presentation is scheduled for November 4, 2026, at 1:35 pm MT at the Hilton Denver City Center.
Chief Medical Officer Sarah Browne, M.D., will present the data.
The presentation title cites reduction in MRI-PDFF and weight loss with relative preservation of lean mass in a randomized placebo-controlled trial.
A poster will be posted on the MetaVia website after the presentation.
EM&T reported that all 57 containers of ULVAC sintered magnet-production equipment have arrived at its expanded Pohang, South Korea facility, with commissioning scheduled to begin in November 2026. The company also signed an investment framework with Pohang City that it expects to bring approximately US$28 million in local government grant funding. The filing is an operational update with no financial results, so it gives shareholders no new revenue, profit or guidance figures.
All 57 containers of ULVAC equipment have arrived at the Pohang facility; commissioning is scheduled to begin in November 2026.
The company expects planned capacity to rise from approximately 1,000 to approximately 10,000 metric tons annually, once installation and commissioning are completed.
An investment framework with Pohang City was signed on October 27, 2026; approximately US$28 million in local government grant funding is expected, subject to conditions.
A ribbon-cutting ceremony and operational showcase is scheduled for December 17, 2026.
D-Wave and South Korean AI company LG CNS signed a non-binding memorandum of understanding to advance adoption of D-Wave's annealing quantum computing for enterprise optimization in South Korea and internationally. The separate announcement that customer Shionogi won a NEDO Challenge prize is a collaboration milestone, and the filing gives no financial terms or revenue figures for either item.
MOU with LG CNS announced October 28, 2026 at D-Wave's Qubits Asia conference in Seoul; it is non-binding.
Companies plan joint applications for manufacturing, telecommunications, finance and retail customers and joint go-to-market efforts.
Customer Shionogi won first place in the NEDO Challenge Quality of Life category, with a ¥40 million prize.
In a Scientific Reports study, 97% of molecules generated by the quantum-assisted model were chemically valid, versus 73% for an equivalent classical model.
Genprex said research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, November 4-7, 2026. The work examines the TUSC2 gene, used in its lead oncology candidate REQORSA, in mitochondrial biology and aging-related processes. The company said further research is needed to determine whether the findings could support future therapeutic development.
Poster titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for Wednesday, Nov. 4, 2026, 6:00-7:15 p.m. ET
Presenter is Mark S. Berger, MD, Chief Medical Officer of Genprex
Collaboration with Meharry Medical College was established in 2024
The filing does not state any financial terms or effects on the company's results
Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis trial of ATR 1072, its lead investigational therapy for PRKAG2 syndrome, a rare genetic heart disease with no approved therapies. The company expects initial proof-of-concept data in the second half of 2027, so the milestone does not yet bear on the company's clinical or financial results.
First patient dosed in the Corventis trial, announced October 27, 2026
Global trial plans to enroll approximately 37 participants
Initial proof-of-concept data expected in the second half of 2027
Primary endpoint is incidence of treatment-emergent adverse events
CDT Equity entered an evaluation agreement dated October 22, 2026, under which Manoira Corporation will assess CDT's clinical-stage compounds AZD1656 and AZD5904 for its animal healthcare products. CDT issued 1,347,616 common shares at $0.1447 per share to settle a $195,000 payment due to Manoira, and the filing also reports other share issuances in the same period. Because the deal is an evaluation with no stated licensing terms yet, its value to shareholders is not yet clear, while the share issuances add to the number of shares outstanding.
Evaluation agreement with Manoira dated October 22, 2026; Manoira is preparing a first range of animal health products for launch in the first quarter of 2027.
1,347,616 shares issued at $0.1447 per share to settle a $195,000 payment to Manoira.
Other unregistered issuances: 397,374 shares to a service provider, 437,779 shares to Sarborg Limited, and 499,616 shares to former CEO Dr. Andrew Regan in lieu of $65,000 severance.
Dr. Regan, a more-than-5% holder and sole director of Manoira, will receive no consideration from the Manoira deal; the filing lists one date as October 23, 3026, which appears to be a typo.
60 Degrees Pharmaceuticals announced clinical improvement and negative conventional PCR results in all five patients who completed treatment in its expanded access babesiosis study, with four of five also NAT-negative on a highly sensitive post-treatment test. The company says the study remains open pending potential discussions with the FDA, and the filing reports no financial results, so the update is clinical and regulatory rather than a measure of current business performance.
All five completed patients were much or very much improved and tested negative on conventional PCR
Four of five completed patients (80%) were nonreactive on post-treatment blood-donor NAT testing
Two additional patients remain on treatment, bringing total enrollment to seven
Tafenoquine is not FDA-approved for babesiosis; the hospital-setting randomized study is expected to unblind in January 2027
Perpetua Resources amended warrants covering 1,607,802 common shares, extending each expiry by up to six months. Its subsidiary also entered a cost-share Tungsten OTIA with the U.S. Army to evaluate tungsten concentrate production at the Stibnite Mining District, with a total estimated cost of up to about $85 million and a cost-share of up to $45 million. The filing gives shareholders a clearer view of potential dilution timing and a new federal-funded exploration program, though the filing notes later phases depend on future approvals and results.
Warrants for 1,607,802 common shares at $31.46 and $38.93 had original expiries of October 28, December 1 and December 23, 2026; each is extended by up to six months.
Tungsten OTIA total estimated cost is up to about $85 million, with cost-share of up to $45 million over a period ending October 19, 2029.
Subsidiary Perpetua Resources Idaho will match the U.S. Army's $40 million contribution; the initial 18-month phase is expected to cost about $18 million, shared equally.
LQR House said its subsidiary YHC AI Limited signed a supplemental agreement giving Fusion Five access to several OpenAI GPT models and raising the ceiling on AI compute purchases under an agreement announced October 19. The filing contains no revenue, earnings, or financial impact figures, so its effect on shareholders is not quantified.
Agreement builds on the up to $3 million AI computing resources deal announced October 19, 2026.
Access covers GPT-6 Astra, GPT-6 Sol, GPT-5.6 Luna, and GPT-5.6 Sol models.
Volume discount of 40% off headline price for purchases between $3 million and $5 million; original 30% discount applies below $3 million.
Filing furnished under Item 7.01 and not deemed filed under Section 18 of the Exchange Act.
Forum Markets said its joint venture Forum Edge AI LLC signed a definitive agreement with Fireworks for a 36-month reservation of Nvidia B300 GPU capacity at a Dallas data center, with a combined total contract value of approximately $94.4 million. The company described it as the first finalized contract for Forum Edge and said the GPUs are expected to be deployed in late December or early January. The filing gives no revenue, profit or cash flow figures, so the contract's effect on the company's financial results cannot be measured from this filing.
Contract value of approximately $94.4 million over a 36-month term
Covers reservation of 96 enterprise AI servers at Edge Node's Dallas data center, per the 8-K body; press release cites Nvidia B300 GPU capacity
Fireworks provided a substantial prepayment deposit, to be credited against fees due
GPU deployment expected in late December or early January; first contracted customer commitment for Forum Edge
SS Innovations said its SSi Mantra robotic system and SSi MantrAsana tele-surgeon console were used in telesurgeries at two October 2026 medical conferences, in Barcelona and New Delhi. The filing is a promotional update and contains no financial results, guidance or financial statements, so it gives shareholders no new financial measures to assess.
Dr. Sudhir Srivastava performed a robotic cardiac telesurgery at the EACTS Annual Meeting in Barcelona, with the patient about 7,500 miles away in Bengaluru, India.
Four surgeons completed four robotic-assisted telesurgeries at the inaugural SRS India Conference in New Delhi.
As of October 23, 2026, a total of 205 telesurgeries had been performed with the SSi Mantra surgical robotic system.
Treasure Global's subsidiary Tadaa Technologies signed a Software Development Agreement on October 21, 2026, with Techcom Vintage Sdn Bhd to build a centralized fertilizer subsidy traceability and AI agriculture platform. Tadaa will pay fixed fees of RM8,000,000 in six milestone payments, and the Developer must deliver the platform in phases over about ten months from the effective date.
Fixed software development fees of RM8,000,000, with a mobilization payment of RM4,000,000 due within two business days after signing
Five delivery phases, with Phase 1 due within one month of October 21, 2026 and final integration due within ten months
Developer pays liquidated damages of 2% of a delayed phase's value per week, capped at 10%; Tadaa owns the resulting intellectual property
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in patients with systemic sclerosis, a rare disease. The company said the results support the drug's safety and tolerability in this population. The filing does not include efficacy data, financial figures, or guidance.
Trial: Phase 2a ASSIST-SSc evaluating oral ifetroban for systemic sclerosis
Announced October 23, 2026, with the press release furnished as Exhibit 99.1
Company states results support safety and tolerability of ifetroban in this rare disease population
Allegiant Air, a subsidiary of Allegiant Travel Company, exercised the first six options under its 2021 Boeing purchase agreement, with the six 737-8 aircraft scheduled for delivery in 2028, at a list price of more than $720 million before discounts and escalations. The company also entered into new employment agreements with four executive officers, including CEO Gregory Anderson, that run through the end of 2029.
Options for six 737-8 aircraft exercised; after this, the purchase agreement has 56 firm aircraft (22 delivered through October 23, 2026) and 74 remaining options.
List price of the six aircraft totals more than $720 million, subject to discounts and price escalations through delivery.
Agreements dated as of October 22, 2026 for Gregory Anderson (CEO, $750,000 base salary, 180% target cash bonus), Robert Neal (president and CFO, $525,000), and Drew Wells and Tyler Hollingsworth ($475,000 each).
All four employment agreements expire at the end of 2029; the Anderson agreement supersedes his 2024 agreement.
High Roller Technologies announced the commercial launch of ROLR, its real-money prediction markets platform, for eligible U.S. customers following a closed beta that began September 15, 2026. The company expects the prediction markets business to begin contributing revenue in the fourth quarter of 2026, a timeline the filing presents as expected rather than confirmed.
Commercial launch announced October 21, 2026, after an invitation-only beta that began September 15, 2026
Prediction markets business expected to contribute revenue beginning in Q4 2026; no revenue figures disclosed
Platform offers event-based contracts from Crypto.com | Derivatives North America; customer accounts are carried by Crypto.com FCM
Marketing partners include Lines.com, Forever Network, Leverage Game Media and SpikeUp Media
Lee Enterprises and its majority-owned subsidiary BLOX Digital each signed a three-year Master Service Agreement with Quintype Solutions LLC on October 16, 2026, for software development services. Quintype is a related party because Quint Digital, which owns about 14.38% of Lee's common stock, holds more than a 10% membership interest in it. The company expects the engagements to generate aggregate annual net savings of more than $1 million once fully implemented, with no minimum spending commitment.
Agreements dated October 16, 2026, were signed by Lee and BLOX Digital, each with Quintype Solutions LLC, for software development services.
Each agreement has a three-year initial term, renews automatically for one-year terms, and bills on a time-and-materials basis with no minimum spend.
Lee expects aggregate annual net savings of more than $1 million once fully implemented; liability is generally capped at fees paid over the prior 24 months.
Sponsor 21Shares US LLC gave notice on October 16, 2026 to terminate its marketing and sub-advisory agreement with ARK Investment Management, effective December 22, 2026. The Trust plans to rename itself 21Shares Bitcoin ETF and change its Cboe BZX ticker from ARKB to TBIT on December 15, 2026.
Notice of termination given to ARK Investment Management on October 16, 2026
Termination effective December 22, 2026
On December 15, 2026, the Sponsor intends to rename the Trust to 21Shares Bitcoin ETF
AmeriServ Bank, a unit of AmeriServ Financial, has transitioned its investment services program to the Ameriprise Financial Institution Group, according to an October 22, 2026 press release filed with the SEC. The filing states that the bank's financial advisors help clients manage approximately $525 million in assets across Pennsylvania and Western Maryland. The filing does not report financial results or a dollar value for the transaction.
Investment services program transitioned to Ameriprise Financial Institution Group (AFIG), announced October 22, 2026
Financial advisors help clients manage approximately $525 million in assets across Pennsylvania and Western Maryland
Company reports $2.8 billion of customer assets under management and administration, and total assets of $1.45 billion as of September 30, 2026
Chairman J. Michael Adams, Jr. said the partnership is designed to grow the AmeriServ Wealth Management complex
Tucows subsidiary Ting Fiber agreed on October 21, 2026 to transfer its dark fiber lease with Colorado Springs Utilities to Google Fiber Colorado, LLC, with closing expected March 31, 2027. Tucows' parent guaranty of Ting's lease obligations, which the company previously estimated at about $322.8 million for the remaining term, is expected to terminate by the end of April 2027, and the company describes the move as part of its ongoing strategic process for Ting.
Ting Fiber entered the Novation Agreement with Google Fiber Colorado, LLC on October 21, 2026; closing is set for March 31, 2027, subject to customary conditions.
Tucows' Parent Guaranty is expected to terminate by the end of April 2027, after closing and certain post-closing obligations to Colorado Springs Utilities are satisfied.
Ting's aggregate lease payment obligations were estimated at approximately $322.8 million for the remaining term, per the Form 10-Q for the quarter ended June 30, 2026.
Ting will keep serving Colorado Springs customers through a transition to be completed no later than June 30, 2027; customers need take no action now.
Edible Garden entered a Produce Supply Agreement with Caney Fork Farms, LLC, effective October 15, 2026, for purchasing and reselling fresh produce for its core herb business. The contract sets fixed pricing through January 31, 2027, runs until October 15, 2028, and gives the company a right of first offer on related supplier opportunities.
Agreement dated October 16, 2026, effective October 15, 2026, with Caney Fork Farms, LLC
Fixed pricing through January 31, 2027; later annual increases capped at the lesser of the Producer Price Index change or 10%
Company must pay for planted products and packaging if it cuts weekly orders below guaranteed minimums with less than 90 days' notice
Term runs to October 15, 2028, with automatic one-year renewals unless either party gives 60 days' notice
Reborn Coffee entered a Master Product Supply Agreement with Visvita Corporation dated October 11, 2026, under which it will sell aloe vera beverages and other products on a non-exclusive basis through purchase orders. The parties agreed to try to reach a $30 million minimum business volume in the first contract year, and an initial $2 million purchase order was signed; the filing does not report financial results. Shareholders should note that the $30 million figure is a target and each order is binding only after the company accepts it.
Agreement dated October 11, 2026; supply is non-exclusive, and purchase orders bind only after written acceptance by the company.
Parties agreed to try to achieve a $30 million business volume minimum in the first contract year; an initial $2 million purchase order was entered into.
The company sets supply prices with a profit margin on each order; payment is due 60 to 120 days after the order is placed with the Korean manufacturer.
Term is two years from October 11, 2026, renewing yearly unless notice is given at least 60 days before expiration; Visvita's president, Michael Aminpour, also serves as the company's Head of Global Sales Advisory.
First Breach announced that its drone prototype reached 161 km/h (100 mph) in flight testing without a payload, the maximum groundspeed the FAA permits under Part 107 without a waiver, and that it is pursuing FAA authorization to test faster. The filing also notes a Chief Revenue Officer presentation at a October 20 investor conference. The filing contains no revenue, earnings, or guidance figures, so it gives shareholders no financial results to judge.
Prototype reached 161 km/h (100 mph) in flight testing without a payload, above the 120 km/h (74 mph) speed in prior published specifications.
Company is obtaining FAA waivers to test above the Part 107 limit; no waiver timing was given.
Initial prototype completion is targeted for Q4 2026 and scaled production for Q2 2027, with capacity above 2,500 drones per week.
Chief Revenue Officer Ken Leith presented at the LD Micro Main Event on October 20, 2026.
Tron Inc. said its Super Representative node has risen to No. 1 in current rankings, with approximately 3.71 billion delegated TRX tokens as of October 21, 2026. The company also intends to operate multiple nodes to broaden recurring on-chain revenues, though the release gives no financial results or revenue figures.
SR node ranked No. 1 with approximately 3.71 billion delegated TRX tokens as of October 21, 2026
Rise follows official SR election earlier in October 2026
Company intends to operate multiple nodes to expand recurring on-chain revenues
Release cites TRON network stablecoin activity of over $94 billion, more than 50% of global USDT circulation
NextTrip, Inc. announced a joint venture agreement with The Travel Agent Next Door Inc., a Canadian travel agency network, to connect Canadian viewers of JOURNY TV with travel booking through JOURNYGO Travel. NextTrip will generate travel inquiries and receive a share of remaining booking commissions, while the partner handles advisor service, booking and fulfillment. The filing gives no financial terms, revenue figures or launch date, so the near-term effect on shareholders is unquantified.
Partner network has 1,850 agents and C$620 million in annual travel sales
NextTrip receives a share of booking commissions remaining after advisor compensation or specified customer service costs
Launch timing and specific program offerings will be announced as implementation progresses
Supplier sponsorship support has not been committed under the agreement
Anavex said it has finished clinical conduct of two pharmacology studies of blarcamesine, an ADME study and a DDI study, both in healthy volunteers. The company said full safety and pharmacokinetic data analysis is still ongoing, and it expects the data to support its FDA-focused development program.
DDI study: last participant completed at the end of September 2026; 65 participants, all received 30 mg
ADME study: last participant completed in mid-October 2026; 8 participants, all received 30 mg
Preliminary observations show no serious adverse events reported; full analysis ongoing
FDA meeting planned for November 2026 on adding pediatric participants to the Rett syndrome Phase 3 study
Deep Fission (Nasdaq: FISN) said it signed a Master Energy Purchase Agreement with the Great Plains Development Authority for a planned commercial nuclear project at the Great Plains Industrial Park in Parsons, Kansas. The 25-year agreement converts a December 2025 letter of intent into a binding contract, but it is subject to regulatory approvals and other conditions, and it has no minimum purchase obligation, so the filing does not quantify its financial effect.
Binding 25-year Master Energy Purchase Agreement with the Great Plains Development Authority, replacing the December 2025 letter of intent
Initial phase of 150 MW with a target commercial operation date of September 30, 2028; later phases could reach 2,000 MW
No minimum purchase obligation; electricity purchases depend on tenant demand and are subject to regulatory approvals
The filing reports no revenue or financial figures for the agreement
Freenome announced on October 20, 2026 the launch of SimpleScreen Lung, a laboratory-developed lung cancer blood test, and an offering that lets eligible patients be screened for lung and colorectal cancer through a single blood draw. The filing reports clinical validation data but no financial results, guidance, or financial terms, so the announcement gives shareholders no direct read on revenue or profit.
SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value in an independent cohort of 172 lung cancer cases and 436 controls.
SimpleScreen Lung has not been reviewed or cleared or approved by the FDA; the SimpleScreen CRC test is FDA-approved for adults 45 and older at average risk.
Abbott has exclusive U.S. commercial rights to SimpleScreen CRC when it is ordered as a standalone test.
The launch was announced October 20, 2026, and the company will show the portfolio at the FMX conference in Nashville, October 20 to 24.
Kartoon Studios said it has contracted with Walmart Marketplace to sell consumer products, such as toys, books and apparel from licensees, based on its HUNDRED ACRE WOOD animated series. The arrangement starts January 18, 2027, and the company expects matching products to be available on Walmart Marketplace at the same time as the series release. The filing gives no financial terms, so its effect on revenue or earnings cannot be measured from this document.
Walmart Marketplace will sell consumer products including toys, books and apparel from licensees.
Products are based on the HUNDRED ACRE WOOD series, which is based on A.A. Milne's Winnie the Pooh.
The arrangement begins January 18, 2027.
The company expects products to be available on Walmart Marketplace concurrent with the series release; no financial terms were disclosed.
Quoin Pharmaceuticals announced the online publication of a peer-reviewed paper introducing its investigational lotion QRX003 and a single pediatric compassionate-use case report. The filing presents single-patient observations only and does not report new trial results, revenue, or financial measures, so the announcement is clinical-awareness news rather than a financial result.
Paper published online October 13, 2026 in Dermatology and Therapy and announced October 20, 2026
Single pediatric patient's IGA score improved from 4 (severe) to 1 (almost clear) after six weeks and reached 0 by eight months
Company expects to complete recruitment of 20 participants in Phase 2/3 study CL-QRX003-004 by end of 2026 and report topline data in Q2 2027
Clene Inc. entered into a subaward amendment on October 15, 2026, for the fourth year of a four-year $45.1 million NIH grant, with New York University receiving up to $7.2 million for the period September 1, 2026 to August 31, 2027. The grant supports an Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis, and the other terms of the subaward remain unchanged. The filing is an administrative funding update under an existing grant rather than a change in the company's financial results or guidance.
Subaward amendment dated October 15, 2026, for up to $7.2 million with New York University
Covers the period September 1, 2026 to August 31, 2027
Part of a four-year, $45.1 million NIH grant announced October 5, 2023
Other subaward terms from the March 16, 2026 filing remain in effect
3M entered into an expanded strategic commercial relationship with a subsidiary of Amazon.com, Inc. and issued that subsidiary a seven-year warrant to buy up to 3,162,015 shares of 3M common stock at $164.89 per share. The filing says 85% of the warrant shares vest based on Amazon payments for optical connectivity and other Data Center products, with full vesting once cumulative payments reach $6 billion. For shareholders, the warrant adds potential dilution, though its vesting ties it to future purchases.
Warrant covers up to 3,162,015 shares of 3M common stock over seven years
Exercise price is $164.89 per common share
85% of warrant shares vest with Amazon payments for optical connectivity and other Data Center products; full vesting at $6 billion in cumulative payments
Remaining warrant shares vest subject to event-based milestones not specified in the filing
LQR House said its subsidiary YHC AI Limited signed a one-year agreement to procure up to $3 million in AI computing resources powered by OpenAI technologies for Fusion Five Continents Securities. The filing reports no financial results or guidance, and the amount ultimately payable depends on Fusion Five's deployment requirements and usage during the contract term.
One-year agreement by subsidiary YHC AI Limited to procure up to $3 million in AI computing resources powered by OpenAI technologies.
Resources support AI-driven research, quantitative analytics and portfolio optimization at Fusion Five Continents Securities, including access to the latest GPT models available in Singapore.
A $30,000 deposit has been paid; the remaining amount payable depends on Fusion Five's usage during the contract term.
Disclosed under Item 7.01 with press release Exhibit 99.1 dated October 19, 2026; no earnings or guidance included.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.